source
- Biogen adds more immune drugs in $1B buyout of secretive startup RayTheraThe companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues.BioPharma Dive · 1mo ago↗ source
- Pfizer CFO to step down; Denali sells a regulatory fast-passA search is underway for a successor to Dave Denton, who took a job outside the pharmaceutical industry. Elsewhere, a new kind of Duchenne gene therapy got venture backing and a GSK deal paid divid…BioPharma Dive · 1mo ago↗ source
- Kardigan extends biotech’s streak of big IPOs with $400M haulIncluding the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.